Clinical trials summary: AGILE


Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

AG120-C-009 (NCT03173248) will evaluate the efficacy and safety of AG-120 (ivosidenib) plus azacitidine vs. placebo plus azacitidine in adult subjects with previously untreated IDH1m AML who are considered appropriate candidates for non-intensive therapy.

The primary endpoint of this global, phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial is overall survival. Key secondary efficacy endpoints are event-free survival, rate of complete remission, rate of complete remission with partial hematologic recovery, and overall response rate. Subjects will be randomized 1:1 to receive either oral AG-120 or matched placebo, both administered in combination with subcutaneous or intravenous azacitidine. An estimated 392 subjects will participate in the study, which is sponsored by Agios Pharmaceuticals. Estimated completion date is June 2022.

Locations: UCLA Medical Center, Los Angeles; Illinois Cancer Specialists, Niles, Illinois; Indiana Blood and Marrow Transplantation, Indianapolis; Norton Cancer Institute, Louisville, Kentucky; Stony Brook University Medical Center, Stony Brook, New York; Duke University Medical Center, Durham, North Carolina; Gabrail Cancer Center, Canton, Ohio; Oncology Hematology Care, Inc., Cincinnati, Ohio; Greenville Health System Cancer Institute, Greenville, South Carolina; Baylor Research Institute, Dallas.

Contact: Medical Affairs Agios Pharmaceuticals, Inc.; (844) 633-2332, e-mail:

Next Article:

   Comments ()

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge